Journal of Clinical Oncology
Articles in this Issue
Effectiveness of the Automated Heart-Health Assessment (AH-HA) tool on cardiovascular health improvements among post-treatment cancer survivors: 12-month results from WF-1804CD.
12019 Background: Cardiovascular disease causes significant morbidity and mortality among US survivors. To enhance guideline recommended cardiovascular he...
Longitudinal tissue analysis and correlation of microenvironmental changes with combined immunotherapy and targeted therapy response in metastatic breast cancer.
1022 Background: The ability to interrogate changes within the tumor microenvironment before, during and following therapeutic intervention could yield im...
Clinical utility of circulating tumor RNA (ctRNA) in a combined circulating tumor DNA (ctDNA) and ctRNA next-generation sequencing (NGS) pan-cancer liquid biopsy assay.
3016 Background: Liquid biopsies are increasingly used in the real world for cancer therapy selection, disease monitoring, and early detection. Combining...
Mechanisms of resistance to anti-PD1 treatment in recurrent and/or metastatic squamous cell carcinoma of the head and neck: A multi-omics IMMUCAN/EORTC analysis.
6050 Background: Anti-PD1 therapies improve overall survival (OS) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN), but...
ETCTN 10563: A phase I study of peposertib and liposomal doxorubicin for advanced or metastatic leiomyosarcoma and other sarcomas.
TPS11585 Background: Soft tissue sarcomas (STS) with genomic complexity are often aggressive but may be sensitive to further genotoxic stress. Leiomyosarc...
Allogeneic stem cell transplantation in chronic myelomonocytic leukemia: Analysis of post-transplant survival and risk factors in 138 Mayo Clinic patients.
6558 Background: Allogeneic stem cell transplantation (ASCT) is currently the only curative therapy in chronic myelomonocytic leukemia (CMML)....
Investigation of pharmacodynamic and prognostic potential of FAP-activity assessed through FAP-mediated cleavage of type III collagen in patients with PDAC undergoing chemotherapy.
e15051 Background: The purpose of the study was to investigate the pharmacodynamic and prognostic potential of FAP-cleaved type III collagen (C3F), a sero...
Evaluation of tumor immune microenvironment in Hispanic and African American breast cancer.
1051 Background: Hispanics or Latinos (HL) and African Americans or Black (AA) have a higher prevalence of advanced-stage breast cancer (BC) at diagnosis...
Best practices and key barriers for light chain (AL) amyloidosis patient care at US specialized amyloidosis centers: An analysis of ARC-ASPIRE.
e13574 Background: AL (amyloid light chain) amyloidosis is associated with poor prognosis especially if diagnosis occurs with cardiac involvement. Current...
Logic-gated, allogeneic Tmod chimeric antigen receptor T-cell (CAR T) therapy targeting epidermal growth factor receptor (EGFR) in advanced solid tumors with human leukocyte antigen (HLA) loss of heterozygosity (LOH): DENALI-1 trial.
TPS2677 Background: Despite the success in hematologic malignancies, CAR T therapies face significant challenges in solid...
Towards a standard of care: Comparing stenting and ligation in parotid duct management for oral cancer.
e18124 Background: In oral cancer surgeries requiring resection of the bucco-alveolar complex, ligation of the parotid duct is a standard practice when it...
Cost analysis of pre-treatment dihydropyrimidine dehydrogenase ( <i>DPYD</i> ) genotyping to reduce hospitalizations at a cancer center in the United States (U.S.).
3097 Background: Patients with certain DPYD variants are at increased risk of fluoropyrimidine (FP) related adverse events (AEs) a...
Treatment preferences of patients, caregivers, and physicians in follicular lymphoma (FL): A global discrete-choice experiment (DCE) study.
11109 Background: While recent FL therapy advances offer various treatment options, data are limited on FL treatment preferences in the shared decision-ma...
Clinicopathological characteristics and survival outcomes in adults with acute megakaryoblastic leukemia: A single-center retrospective analysis.
e18525 Background: Acute megakaryoblastic leukemia (AMKL, AML-M7) is a rare, biologically heterogeneous type of Acute Myeloid Leukemia (AML) arising from...
Impact of MGMT methylation on overall survival in solid tumors: A systematic review and meta-analysis.
3146 Background: The protein O6-alkylguanine-DNA-alkyltransferase (AGT), encoded by the MGMT gene, plays a crucial role in DNA repair by singularly removi...
Advancing gender-responsive cancer control: A mixed methods evaluation of the leadership program for women in oncology.
9033 Background: Women constitute nearly 70% of the global health and social workforce but hold only 25% of senior leadership roles. Increasing women's re...
MK-1084 for KRAS G12C-mutated (mut) metastatic non–small-cell lung cancer (mNSCLC): Results from KANDLELIT-001.
8605 Background: MK-1084 is an oral, next-generation, selective KRAS G12C-GDP covalent inhibitor. The phase 1 KANDLELIT-001 study (NCT05067283) showed man...
Global burden of lip, oral, and pharyngeal cancer across three decades: An age-adjusted GBD analysis.
e18138 Background: Lip, oral, and pharyngeal cancers (LOPC) are significant contributors to the global cancer burden, with notable disparities across regi...
Leveraging artificial intelligence (AI) to optimize multidisciplinary tumor board workflows at OSF HealthCare’s network of cancer centers.
e13604 Background: In recent decades, technological advancements and personalized medicine have made cancer care increasingly complex, requiring collabora...
A real-world study of the association between nivolumab exposure and efficacy in patients with metastatic melanoma.
e15126 Background: The pharmacokinetic/pharmacodynamic (PK/PD) relationships of immune checkpoint inhibitors are not well understood. In this real-world s...
Novel early-detection model based on cfDNA methylation and fragmentation features for liver cancer.
4133 Background: In China, the 5-year survival rate of liver cancer patients is only 14%, far lower than the average of 43.7% for all cancer types. Early...
Disparities in GLP-1 receptor agonist prescriptions among breast cancer survivors with type 2 diabetes.
e13831 Background: GLP-1 receptor agonists (GLP-1RA) improve glycemic control, promote weight loss, and reduce cardiovascular risks in patients with type...
Impact of time to relapse (TTR) and metastasectomy (MTS) on survival in leiomyosarcoma (LMS): A CanSaRCC study.
11567 Background: Approximately 40% of LMS patients (pts) experience relapse despite standard care of surgical resection ± radiotherapy. Upon relapse, pts...
The impact of neoadjuvant chemotherapy (NAC) ± anti-HER2 antibodies (mAbs) on gut microbiome composition in early breast cancer (EBC): A pilot prospective study.
e12626 Background: Gut microbiome composition and its changes induced by chemotherapy ± anti-HER2 monoclonal antibodies (mAbs) in breast cancer patients a...
Heterogeneity in the expression of GPRC5D between patients with multiple myeloma.
7511 Background: G-protein-coupled receptor class C group 5 member D (GPRC5D) is a protein inducible by all-trans retinoic acid with expression levels tha...